B of A Securities Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Buy rating on Biomarin Pharmaceutical but lowered the price target from $130 to $115.

September 17, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
B of A Securities has maintained a Buy rating on Biomarin Pharmaceutical but lowered the price target from $130 to $115, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in Biomarin's prospects, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100